Abstract
MR spectroscopy opens a window to the non-invasive evaluation of various aspects of cardiac metabolism. Experimentally, the method has extensively been used since 1970's. 31P-MR allows the registration of cardiac high-energy phosphate metabolism to non-invasively estimate the energetic state of the heart: ATP, phosphocreatine, inorganic phosphate, monophosphate esters and intracellular pH can all be quantitated. In conjunction with extracellular shift reagents such as [DyTTHA]3- or [TmDOTP]5-5-, 23Na- and 39K-MR allow the measurement of intra- and extra-cellular cation pools. 1H-MR spectroscopy allows the detection of a large number of metabolites such as, e.g. creatine, lactate, or carnitine.
Human cardiac spectrocsopy has so far been confined to the31 P nucleus. Localization techniques (DRESS, ISIS, 3D-CSI etc.) are required to confine the acquired signal to the heart region. Relative quantification is straightforward (phosphocreatine/ATP ratio), absolute quantification (mM) is under development. Cardiac31 P-MR spectroscopy has research application in at least three clinical areas: (1) Coronary artery disease: A biochemical stress test for non-invasive ischemia detection (decrease of phosphocreatine with exercise) and viability assessment via quantification of ATP may become feasible. (2) Heart failure: The phosphocreatine /ATP ratio may provide an independent index for grading of heart failure, allow to monitor the longterm effects of different forms of drug therapy on cardiac energy metabolism in heart failure, and may also hold prognostic information on survival. (3) Valve disease: It is possible that the decrease of phosphocreatine/ATP can be used to guide the timing for the valve replacement.
At the present time, no routine clinical applications can be defined for the use of human cardiac spectroscopy in patients with cardiac disease. However, the technique holds great potential for the future as a non-invasive approach to cardiac metabolism, and in coming years routine applications may become reality.
This is a preview of subscription content, log in via an institution to check access.
References
Ingwall JS: Phosphorus nuclear magnetic resonance spectroscopy of cardiac and skeletal muscles. Am. J. Physiol 242: H729–H744, 1982
Neubauer S, Ertl G, Krahe T, Schindler R, Hillenbrand H, Lackner K, Kochsiek K: Experimentelle und klinische Möglichkeiten der MRSpektroskopie des Herzens. Z Kardiol 80:25–36, 1991
Gadian DG: Nuclear Magnetic Resonance and Its Applications to Living Systems. Oxford University Press, New York, 1982
Malloy CR, Sherry AD, Jeffrey FMH: Substrate metabolism in the citric acid cycle of the heart by 13C NMR. Kluwer Academic Publishers, Boston, Dordrecht, London 153–168, 1992
Weiss RG, Chacko VP, Glickson JD, Gerstenblith G: Comparative 13C and 31P NMR assessment of altered metabolism during graded reductions in coronary flow in intact rat hearts. Proc Natl Acad Sci USA 86: 6426–6430, 1989
Bottomley PA: MR spectroscopy of the human heart. The status and the challenges. Radiology 191: 593–612, 1994
Bottomley PA, Atalar E, Weiss RG: Human cardiac high-energy phosphate metabolite concentrations by 1 D-resolved NMR spectroscopy. MRM 35: 664–670, 1996
Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, Entzeroth C, Kromer EP, Riegger AJG, Lackner K, Ertl G: Cardiac 31P-magnetic resonance spectroscopy of volunteers and patients with coronary artery disease and dilated cardiomyopathy. Altered cardiac highenergy phosphate metabolism in heart failure. Circulation 86: 1810–1818, 1992
Weiss RG, Bottomley PA, Hardy CJ, Gerstenblith G: Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. New Engl J Med 323: 1593–1600, 1990
Yabe T, Mitsunami K, Okada M. Morikawa S, Inubushi T, Knoshita M: Detection of myocardial ischemia by 31P magnetic resonance spectroscopy during handgrip exercise. Circulation 89: 1709–1716, 1994
Yabe T, Mitsunami K, Inubushi T, Kinoshita M: Quantitative measurements of cardiac phosphorus metabolites in coronary artery disease by 31P magnetic resonance spectroscopy. Circulation 92: 15–23, 1994
Neubauer S, Horn M, Pabst T, Gödde M, Lübke D, Illing B, Hahn D, Ertl G: Contributions of 31P-magnetic resonance spectroscopy to the understanding of dilated heart muscle disease. Eur Heart J 16 (suppl. O): 115–118, 1995
Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G: Altered myocardial high-energy phosphate metabolism in patients with dilated cardiomyopathy. Am Heart J 122: 795–801, 1991
De Roos A, Doornbos J, Luyten PR, Oosterwaal LJMP, van der Wall EE, den Hollander JA: Cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy: Assessment with protondecoupled P-31 MR spectroscopy. JMRI 2: 711–719, 1992
Neubauer S, Horn M, Cramer M, Harre K, Newell JB Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K: In patients with dilated cardiomyopathy the myocardial phosphocreatine-to-ATP ratio is a predictor of mortality. Circulation 96: 2190–2196, 1997
Conway MA, Allis J, Ouwerkerk KR, Niioka T, Rajagopalan B, Radda GK: Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet 338: 973–976, 1991
Hetherington HP, Luney DJE, Vaughan JT, Pan JW, Ponder SL, Tschendel O, Twieg DB, Pohost GM. 3D 31P spectroscopic imaging of the human heart at 4.1 T. Magn Reson Med 33, 3: 427–431, 1995
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Neubauer, S., Horn, M., Hahn, D. et al. Clinical cardiac magnetic resonance spectroscopy - present state and future directions. Mol Cell Biochem 184, 439–443 (1998). https://doi.org/10.1023/A:1006803731763
Issue Date:
DOI: https://doi.org/10.1023/A:1006803731763